Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-951 in Healthy Subjects
NCT06610279Phase 1Terminated
- Sponsor
- Takeda
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-951 in nausea ((none)) and Vomiting (9 arms), sponsored by Takeda. Primary endpoint: Treatment-emergent Adverse Events at Day 27. Started Jan 2022; status: terminated.
02
Drugs
TAK-951
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT06610279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610279.